

AUSTRALIA
NEW ZEALAND
IBD CONSORTIUM

Australian New Zealand Inflammatory Bowel Disease Consortium

Annual Report 2021



FOREWORD

On behalf of the ANZ IBD Consortium it is with great pleasure that I introduce our 2021 annual report. 2021 was a year of restructure and change with the selection of a new executive committee, introduction of a scientific committee, employment of a new project manager and change of lead site from the Queensland Institute of Medical Research Berghofer to Mater Research. We would like to acknowledge the efforts of A/Prof Graham Radford-Smith in establishing the consortium, and of Graham and Krupa Krishnaprasad for overseeing its operation for over 12 years and all of their achievements during this time. The new committee members certainly have high standards to uphold, and we look forward to working collaboratively to maintain the consortium's success.

During 2021, we have continued to undertake many of our ongoing studies, commenced a number of new studies, applied for a number of competitive grants and continued to publish our results. The website has been transformed, we have started our social media pages on twitter, Facebook and LinkedIn and we have rolled out our regular quarterly newsletters to keep all of our members up to date with ongoing research, processes and procedures and other consortium activities.

We are proud that in 2021 we generated interest from international collaborators including GETaid and the Korean Association for the Study of Intestinal Diseases as well as local research groups to collaborate on innovate research in our field of Inflammatory Bowel Disease.

We would like to thank all of the members for their ongoing participation and support and recognize the contributions not only from our site leads and affiliate members, but the fellows, registrars, research nurses and coordinators that enable the consortium to undertake its research.

We look forward to a highly productive 2022 as we dedicate ourselves to our clinical and academic pursuits and strive towards developing and delivering high quality research projects to improve the lives of those living with Inflammatory Bowel Disease.

A/Prof Jake Begun
ANZIBDC Chair



About Us

The Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC) is a collaborative research group which aims to progress knowledge and clinical practice in the field of IBD through the combination of both clinical and scientific research, thus improving patient outcomes across the Australian and New Zealand populations. It was formed in 2008 and currently comprises 17 IBD centres around Australia and New Zealand. ANZIBDC member centres currently provide IBD care for approximately 20,000 patients which represents around 20% of the population with IBD within Australia and New Zealand.

Our Vision

Our vision is to **improve quality of clinical care and patient outcomes, and ultimately find a cure** for people living with IBD.

Our Mission

Our mission is to provide a collaborative network for high performing research centres to develop and undertake multi-centre clinical and scientific research in IBD. We aim to improve research quality and capability through provision of scientifically rigorous feedback, collaborative resources and improved access to funding. We strive to implement our research outcomes into clinical practice to improve patient quality of life through dissemination of key findings and by leveraging our stakeholder relationships, communications and networks.

Our current strategic priorities include:

1. Supporting ongoing future innovative multicentre clinical trials of existing medications, cohort studies and retrospective trials.
2. Improving patient centred quality of care through projects designed to determine quality and improve models of healthcare delivery.
3. Developing platforms for understanding genetic, microbial and epidemiological determinants in IBD through establishment of an ANZIBDC biobank and data registry.
4. Developing greater support for obtaining independent sustainable funding, through:
 - i. increased grant success (via leveraging the collaborative ANZIBDC network, provision of opportunities to discuss research ideas, provision of scientific feedback to improve on applications),
 - ii. developing strong relationships with sponsors.
5. Maintaining and developing strong partnerships with national and international researchers and research groups, patient groups, industry partners and policy makers.
6. Supporting early career researchers through mentorship and collaborative research.

ANZIBDC Organisation Structure

Executive Committee 2021-2024

Chair: A/Prof Jakob begun

Secretary: Dr Yoon-Kyo An

Treasurer: Dr Simon Ghaly

Communication & Marketing Officer (CMO): Dr Lena Thin

Strategy & Innovation Officer (SIO): A/Prof John Nik Ding

Scientific Committee Representative: A/Prof Peter De Cruz

CCCure Representative: A/Prof Susan Connor

Scientific Committee 2021 – 2023

Chair & SC Representative: A/Prof Peter De Cruz

Chair: A/Prof Jakob Begun

Chair: A/Prof John Nik Ding

SC Member: Prof Michael Schultz

SC Member: A/Prof Miles Sparrow



SC Member: Dr Yoon-Kyo An

Administrating institution: Mater Research

Project Manager: Dr Leonie Ruddick-Collins

Sites	Lead members	Affiliate Member
Mater Hospital	A/Prof Jakob Begun	Dr Yoon-Kyo An
Royal Brisbane & Women's Hospital	A/Prof Graham Radford Smith	
Townsville Hospital	Dr Gillian Mahy	
St Vincent's Hospital Sydney	Dr Simon Ghaly	Dr Andrew Kim
Liverpool Hospital	Dr Astrid-Jane Williams	A/Prof Susan Connor Dr Watson Ng
St Vincent's Hospital Melbourne	A/Prof John Nik Ding	Dr Emily Wright A/Prof William Connell
Alfred Hospital	A/Prof Miles Sparrow	A/Prof Antony Friedman A/Prof Mark Ward Dr Kirstin Taylor
Box Hill Hospital	A/Prof Daniel Van Langenberg	Dr Abhinav Vasudevan
Austin Hospital	A/Prof Peter De Cruz	Dr Matthew Choy Dr Darren Wong
Northern Health	A/Prof Mayur Garg	Dr Soleiman Kashkooli
Monash Health	A/ Prof Gregory Moore	A/Prof Sally Bell Dr Ralley Prentice
Royal Adelaide Hospital	Dr Kate Lynch	Prof Jane Andrews
Flinders Medical Centre	Dr Reme Mountifield	
St John of God Hospital	Prof Ian Lawrance	
Fiona Stanley Hospital	Dr Lena Thin	Dr Jesica Makanyanga Mr Daniel Lightowler
Christchurch Hospital	Prof Richard B Geary	Prof Murray Barclay
Dunedin Hospital	Prof Michael Schultz	

ANZIBDC Organisation Structure



Queensland Members

Mater Misericordiae: Mater Hospital and Mater Research




A/Prof Jakob Begun
Mater Site Lead
ANZIBDC Chair
Science Committee Co-Chair

Prof Jakob Begun is Director of Gastroenterology at Mater Hospital, lead of the IBD group at Mater research and oversees a bioscience lab at translational research institute-University of Queensland. A/Prof Begun has specialist interests in functional genetics of IBD, the role of innate immunity and the microbiome in gut inflammation, and developing novel treatments for IBD.



Dr Yoon-Kyo An
Mater Affiliate Member
ANZIBDC Secretary
Science committee member

Dr Yoon-Kyo An is the Head of Inflammatory Bowel Disease (IBD) at Mater Hospital Brisbane and the Clinical Lead of the IBD Clinical Trials Unit at Mater Research institute. Dr An's research focusses on real-world effectiveness of biologic therapy in IBD and the use of intestinal ultrasound in IBD.



Leonie Ruddick-Collins
ANZIBDC Project
Manager

Royal Brisbane Women Hospital (RBWH) / Queensland Institute of Medical Research (QIMR)



A/Prof Graham Radford-Smith
RBWH Site Lead
ANZIBDC past Chair and founder

A/Prof Graham Radford-Smith is a gastroenterologist at the RBWH and Deputy Director in the Gastroenterology Department and the delivery of IBD services to Metro North, Wide Bay and Central Queensland. A/Prof Radford-Smith is an honorary group leader at the QIMR. A/Prof Radford-Smith has a special interest in the areas of IBD genetics, utilisation of health information to optimise patient care and outcomes; and, the role of the gut microbiome in IBD.

Townsville Hospital and Health Services (THHS)

Dr Gillian Mahy is Clinical lead for Inflammatory Bowel Disease (IBD) services at THHS. Dr Mahy joined the consortium when it commenced in 2008 and contributed substantially to the consortium's projects over the years. Dr Mahy has an interest in regional/rural epidemiology, models of care and delivery in remote settings and understanding different IBD patient healthcare beliefs in non-metro settings.



Dr Gillian Mahy
THHS Site Lead

New South Wales Members

Liverpool Hospital



Dr Astrid-Jane Williams
Liverpool Site Lead

Dr Astrid-Jane Williams is a Staff Specialist in the Gastroenterology Department at Liverpool and Conjoint Lecturer with the University of NSW. Dr Williams contributed to the development of the pregnancy in IBD and paediatric to adult IBD transition care clinics at Liverpool.



A/Prof Susan Connor
Executive committee
CCCure representative

A/Prof Susan Connor is a gastroenterologist and director of the IBD Department at Liverpool hospital as well as a conjoint associate professor with the University of NSW. A/Prof Connor has a passion for improvement of patient care, promoting models for chronic disease management and therapeutic drug monitoring in IBD.



Dr Watson Ng
Affiliate member

Saint Vincent's Hospital Sydney (SVHS)



Dr Simon Ghaly
SVHS Site Lead
ANZIBDC treasurer

Dr Simon Ghaly is a staff Specialist and head of the Inflammatory Bowel Disease service at St. Vincent's Hospital Sydney and conjoint lecturer at the University of New South Wales.

Dr Ghaly bring to the consortium a special interest in the microbiome, faecal transplants and bone health.



Dr Andrew Kim
Affiliate member

Victoria Members

Austin health



A/Prof Peter De Cruz
Austin Site Lead
ANZIDC Scientific committee
Representative
Scientific committee Chair

A/Prof Peter De Cruz is a senior IBD clinician-researcher, the Director of the IBD service at the Austin Hospital and a Senior lecturer at the University of Melbourne.

A/Prof De Cruz's current research focuses on quality improvement, health economics, eHealth, therapeutic drug monitoring and biomarker discovery.



Dr Darren Wong
Affiliate member



Dr Matthew Choy
Affiliate member

Alfred Health



A/Prof Miles Sparrow
Alfred Health Site Lead
Scientific committee member

A/Prof Miles Sparrow is the Director of the IBD Unit at The Alfred Hospital, Melbourne and Adjunct Clinical Associate Professor at Monash University. His research interests include use and optimisation of immunomodulators, therapeutic drug monitoring, novel E-Health models of care in IBD and clinical trials of novel experimental agents in IBD.

Dr. Kirstin Taylor Affiliate member (not pictured)



A/Prof. Antony Friedman
Affiliate member



A/Prof. Mark Ward
Affiliate member

Saint Vincent's Hospital Melbourne (SVHM)




A/Prof John Nik Ding
SVHM Site Lead
Strategy & Innovation Officer

A/Prof John Nik Ding is the head of the IBD Clinical trials Unit at St Vincent's Hospital Melbourne. His research focuses on translational aspects of metabolic profiling and bioinformatics for the discovery of biomarkers along with quality aspects of colonoscopy particularly focusing on the barriers to ensuring quality in colonoscopic evaluation.



Dr Emily Wright
Affiliate member



A/Prof William Connell
Affiliate member

Monash Health




A/Prof Greg Moore is head of IBD in the department of Gastroenterology & Hepatology at Monash Health and Associate Professor in the school of clinical sciences at Monash University.
A/Prof Moore completed his PhD in immunology and novel therapeutics for IBD before establishing the IBD unit at Monash Health with a dedicated clinical trials program.

A/Prof. Gregory Moore
Monash Health Site Lead



A/Prof Sally Bell is a gastroenterologist and hepatologist, and is the Director of Gastroenterology at Monash Health.
A/Prof Bell's current research interests include the epidemiology of IBD, hepatocellular carcinoma, and pregnancy and IBD.

A/Prof Sally Bell
Affiliate member
Previous SVHM lead



Dr Ralley Prentice
Affiliate member

Eastern Health - Box Hill Hospital



A/Prof Daniel Van Langenberg is Head of IBD service and a Senior Gastroenterologist at Eastern Health, and Senior Lecturer at Monash University.
A/Prof Van Langenberg has sat on the Australian IBD Association Executive Committee, overseeing National IBD clinical and research interests, including writing the National IBD guidelines (GESA, 2017).

A/Prof Daniel Van Langenberg
Box Hill Site Lead



Dr Abhinav Vasudevan
Affiliate member

South Australia Members

Royal Adelaide Hospital (RAH)



Dr Kate Lynch is a consultant gastroenterologist and hepatologist and head of the IBD department at Royal Adelaide Hospital.
Dr Lynch has a specialist interest in the gut-liver axis in Primary Sclerosing Cholangitis (PSC) and IBD, as well as IBD biomarkers and transition of healthcare among adolescents from children's services to adult services.

Dr Kate Lynch
RAH Site Lead



Prof. Jane Andrews is a consultant gastroenterologist and the medical stream lead in gastroenterology, general and GI surgery at RAH and Clinical Professor at the School of Medicine, University of Adelaide.
Prof Andrews has a strong interest in clinical audit, value in care, clinical outcomes research and healthcare system delivery.

Prof Jane Andrews
Affiliate Member
(Previous RAH Site Lead)

Northern Health




A/Prof Mayur Garg is Director of Gastroenterology at Northern Health and Clinical Associate Professor at University of Melbourne.
A/Prof Garg has a passion for excellence in patient care and service quality and is a believer in patients participating and being empowered in their management.

A/Prof Mayur Garg
Northern Health Site Lead



Dr Soleiman Kashkooli
Affiliate Member



Dr Réme Mountfield
Flinders Hospital Site Lead

Dr Réme Mountfield is a Senior Consultant Gastroenterologist and the IBD Service Lead at the Southern Adelaide Local Health Network in South Australia, and Senior Lecturer at Flinders University.

Dr Mountfield has a special clinical and research interest in Fertility and Pregnancy challenges in IBD patients, with numerous publications in this field.

Western Australia Members

St John of God Hospital Subiaco (SJOG)

Prof Ian Lawrance is a gastroenterologist and Head of center for IBD at Saint John of God Subiaco where he created the first clinic in 2015. He is also a Professor in the School of Medicine and Pharmacology, Faculty of Medicine and Dentistry at the University of Western Australia.

Prof Lawrance has a special interest in mesenchymal stromal/ stem cells (MSSC) fibrosis, and long-term outcomes to medication use.



Prof Ian Lawrance
SJOG Site Lead

Fiona Stanley Hospital (FSH)



Dr Lena Thin
FSH Site Lead

ANZIBDC Communication &
Marketing Officer

Dr Lena Thin is a Consultant Gastroenterologist and the IBD Research Lead for the IBD unit at Fiona Stanley Hospital.

Dr Thin has a special interest in Metabolic changes with IBD including obesity and body composition influence on biologic efficacy, influence of sex hormones (exploring testosterone use in IBD), and Cardiovascular (MACE) associations with biologic use.



Dr Jesica Makanyanga
Affiliate Member

New Zealand Members

Christchurch Hospital, University of Otago



Prof Richard Gearry
Christchurch Site Lead

Prof Richard Gearry is a consultant Gastroenterologist at Christchurch Hospital and head of the department of medicine at University of Otago, Christchurch.

Prof Gearry has a keen interest in understanding inflammatory bowel disease Epidemiology, Biomarkers, Clinical outcomes and Therapeutics.



Prof Murray Barclay
Affiliate Member

Dunedin Hospital



Prof Michael Schultz
Dunedin Site Lead

Prof Michael Schultz is a consultant Gastroenterologist at Dunedin Hospital and head of the department of medicine at Dunedin School of Medicine, University of Otago, Dunedin.

Prof Schultz has a special interest in IBD at both a clinical and basic research level. His Lab group are working on the role of epithelium in intestinal inflammation with the use of human organoids, animal models and cell cultures.

Updates from the Scientific Committee

Scientific Committee review of 2021

Message from the Chair

The Scientific Committee was established in 2021 to provide Scientific Strategic Direction to the Consortium. The Scientific Committee aims to support ongoing and new projects, maintain accountability for completion of projects and provide scientific feedback to improve project and grant applications.

It was a highly effective year as we spent time developing authorship guidelines, revising the process for applying for Grants and Projects under the ANZIBDC banner and reviewing and providing feedback to a number of project and grant applications. Over the year we had 5 projects submitted for review of which 3 were accepted as meeting the ANZIBDC goals, and 1 still to be confirmed based on gathering further information.

We have been honoured to have been sought out from a number of international groups including GETaid and the Korean IBD group to undertake collaborative projects and are eager to continue to develop the reputation of the ANZIBDC to become the organization to go to for these international groups wishing to collaborate.

A key goal of the Scientific Committee is to maintain accountability for research projects. Thus, we have been following up with leads on completed projects regarding publications and ensuring current projects are running to schedule. In 2022 we will continue to work with ongoing projects to confirm progress and provide any assistance where feasible.

Our goals for 2022 are to:

1. Encourage new ANZIBDC collaborative projects. We are aiming to see at least 1-2 new clinical trials initiated per year, as well as a number of cohort studies and retrospective studies.
2. Gain funding for projects through research grants, philanthropic and sponsorship funding. We would like to see more members share ideas and apply for ANZIBDC support through use of the ANZIBDC project and grant application forms.
3. Focus on Values Based Health Care. We are working towards establishing Australian IBD quality indicators which will be used for reporting and improving on patient clinical care and will continue to seek funding for this initiative.
4. Re-establish the ANZIBDC biobank and a clinical data registry for long term retrospective and prospective research projects.
5. Continue to maintain project accountability and improve rates of publications from ANZIBDC projects.

We look forward to a highly successful year and working with all our members in contributing to the success of ongoing and future ANZIBDC projects.

A/Prof Peter De Cruz

Chair of the Scientific Committee

Scientific outputs - metrics

Projects:



Publications:




Internal Project and Grant applications:



Average turnaround time from submission to feedback: 21 days

External Grants for Project funding:



Project: **P**rospective **R**andomised **C**ontrolled Trial of **A**dult Patients with Perianal Fistulising **C**rohn's Disease and Optimised **T**herapeutic **I**nfliximab **L**evels: PROACTIVE

Lead investigator/s: A/Prof Susan Connor and A/Prof John Nik Ding

Grant Scheme: MRFF-Efficient Use of Existing Medicines 2020

Project Funding received: \$ 834,374

Grant duration: 4 years

Administering institution: University of New South Wales

A major highlight of the year was the successful grant outcome for the 2020 MRFF Efficient Use of Existing Medicines scheme led by A/Prof Susan Connor and A/Prof Nik Ding. Funding was received to support the PROACTIVE (**P**rospective **R**andomised **C**ontrolled Trial of **A**dult Patients with Perianal Fistulising **C**rohn's Disease and Optimised **T**herapeutic **I**nfliximab **L**evels) trial which will evaluate the efficacy of individualised infliximab induction and maintenance therapy in adults with perianal fistulising Crohn's Disease, compared to conventional fixed dosing; incorporating a novel approach aiming at higher drug levels, using proactive therapeutic drug monitoring to guide dose optimisation. The project is to be run over 4 years across 27 Australian centres including 14 of the ANZIBDC sites.

Project: The Study of Tofacitinib for the treatment of chronic PouchITis (STOPit)

Lead investigator/s: A/Prof Jakob Begun and Dr Emi Khoo

Grant Scheme: Pfizer global medical grant and Pfizer ltd

Project Funding received: \$ 56, 000 + compassionately supplied Investigational Product and Placebo

Grant duration: 3 years

Administering institution: Mater Research

A/Prof Jakob Begun and Dr Emi Khoo were successful in receiving funding from the Pfizer global medical grant to cover basic project costs and compassionate drug supply for the STOPit trial. STOPit is a multi-center study designed as an open label induction study followed by a randomized, double blind, placebo-controlled maintenance withdrawal study. The study comprises two phases: An 8-week induction phase, with optional 8-week extension for non-responders, followed by a 24-week maintenance phase. The study will evaluate clinical and endoscopic responses, biomarkers and quality of life, before and after commencement of tofacitinib in patients with chronic pouchitis.

Projects

Ongoing


Pregnancy In Crohn's and Colitis: Observations, Levels and Outcomes extension study. (PICCOLO-X)

Project lead: A/Prof Sally Bell

Lead institution: Monash

ANZIBDC sites involved: 13 ANZIBDC sites have contributed to recruitment

Project stage: Recruitment/ Data collection



Australian Ustekinumab Real-world Observation Research (AURORA)

Project lead: A/Prof Jakob Begun and Dr Yoon-Kyo An

Lead institution: Mater Brisbane

ANZIBDC sites involved: 13 Sites activated and 12 contributing to recruitment and data collection

Project stage: Recruitment/ Data Collection



My Actively Informed Decision (MyAID)

Project lead: A/Prof Susan Connor

Lead institution: Liverpool Hospital

ANZIBDC sites involved: 12 Sites activated contributing to recruitment and data collection

Project stage: Data Collection / Data analysis for 6-month outcomes



New Projects starting in 2021

Prospective Randomised Controlled Trial of Adult Patients with Perianal Fistulising Crohn's Disease and Optimised Therapeutic Infliximab Levels (PROACTIVE)

Project lead: A/Prof Susan Connor

Lead institution: Liverpool Hospital

ANZIBDC sites involved: 14 ANZIBDC sites to be onboarded of 27 sites total

Project stage: Study Start Up. Study active at Liverpool and other sites being onboarded.



Study of TOfacitinib for the treatment of chronic PouchITis (STOPit)

Project lead: A/Prof Jakob Begun and Dr Emi Khoo

Lead institution: Mater Brisbane

ANZIBDC sites involved: 9 ANZIBDC sites will take part

Project stage: Study Start Up. Study active at Mater.



Projects In Development

A Delphi protocol to develop Australian and New Zealand Inflammatory Bowel Disease Quality Indicators

Project lead: Peter De Cruz

Project stage: Planning

Publications:

Member wide Publications

Accepted:

De Gregorio M, Lee T, Krishnaprasad K, Amos G, An Y-K, Bastian-Jordan M, . . . Cheung W. Higher Anti-tumor Necrosis Factor- α Levels Correlate With Improved Radiological Outcomes in Crohn's Perianal Fistulas. Clin Gastroenterol Hepatol. 2021. Aug 11:S1542-3565(21)00865-X. doi: 10.1016/j.cgh.2021.07.053. Epub ahead of print.

Submitted:

Lim E., Thai M, An Y, Hendy P, Alchlahiawi M, Leong R. ...Begun J. Endoscopic balloon dilatation has a high success rate and appears to reduce the need for surgery in patients with stricturing Crohn's disease. Under Review

Mortlock, S., Lord A, Montgomery G, Zakrzewski M, Simms LA, Krishnaprasad K. An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. bioRxiv 2021.10.04.462982; doi: <https://doi.org/10.1101/2021.10.04.462982>

Publications from member's projects:

Flanagan E, Wright EK, Hardikar W, Sparrow MP, Connell WR, Kamm MA, ...Bell SJ; PICCOLO Study Group. Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Aliment Pharmacol Ther. 2021;53(7):810-820.

Flanagan E, Wright EK, Sparrow MP, Moore GT, Connell WR, De Cruz P, . . . Bell SJ; PICCOLO Study Group. A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive. Inflamm Bowel Dis. 2021.

Kim AH, Girgis A, De Cruz P, Siegel CA, Karimi N, Ruban SO, Sechi AJ, Ng WSW, Andrews JM, Connor SJ. Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. J Med Internet Res.2021;23(2):e15946

Prentice RE, Wright EK, Flanagan E, Ross AL, Bell SJ.J . Vedolizumab safety in pregnancy: Extricating drug from disease-related effects.. Gastroenterol Hepatol. 2021;36(11):3247-3248.


W Gu, B., De Gregorio, M., Pipicella, J. L., Vande Castele, N., Andrews, J. M., Begun, J., ... Connor, S. Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ open, 2021;11(7): e043921

Overview of the peer review process for project/grant applications

Throughout 2021, the scientific committee have been working towards setting up processes and procedures to ensure that we can facilitate our objectives.

This includes formalising the process in which we ask members to apply for ANZIBDC supported projects and grants and the way we provide feedback. This guarantees that we gain adequate information about the project/grant to make a fair decision and provide the feedback and support required.

Application forms are available from the Project Manager or in the members section of the website.



CCCare software was developed by members of the ANZIBD consortium in partnership with Crohn's Colitis Cure (CCC; <http://www.c-c-cure.org>) as a cloud-based IBD specific clinical management system with the capacity to collect patient data and improve quality of patient care. By December 2021, >7000 patients had been entered into the system across 16 Australian and new Zealand sites, including 9 ANZIBDC sites.

CCCare developments

In 2021 one of the main focusses was on the development of the paediatric module "CCCare-P". The development of this module which has now been completely integrated into the existing CCCare software added functionality and resources which caters for the paediatric patient cohort. This endeavour was generously supported by the Leona M. and Harry B. Helmsley Charitable Trust. New features in the paediatrics model include disease activity indices for clinical assessments, questionnaires on mental health, quality of life, self-management and transition, data collection on growth and puberty, phenotyping, diet and nutrition, medication and vaccination review and annual checklist functionality.

CCCare projects

Some noteworthy projects currently underway using the software data include:

ACI Grant for KPI Reporting - Implementing a value-based model of care for improving quality, safety, and cost-effectiveness of care for inflammatory bowel disease. The objective of this study is to use a Value-based models of care (VBMoC), which is an evidence-based solution, to reduce unwarranted variation in care (a key barrier to achieving quality and equity in care). This includes continuous monitoring and reporting, using tailored feedback. The aim of this study is to demonstrate that over a period of 15 months, 3 monthly monitoring of quality metrics and patient outcomes, reporting and coordinated feedback, facilitated through use of the software system CCCare, will result in improvements in quality of patient care and care processes, safety of patient care and reduced health care utilisation.

A Collaboration with Torrens University Australia, entitled "The utilisation of adalimumab weekly dose escalation in patients with IBD treated across key centres in Australia'. The aim of this study is to describe the real-world experience of the need for an outcome from weekly dosing of Adalimumab compares to a usual fortnight dosing in people with Inflammatory Bowel Disease



**Proudly supported by
CELLTRION Healthcare**

**Level 2, Raymond Terrace, South Brisbane Queensland
4101, Australia**

Email: anzibdc@mater.uq.edu.au

Phone: (+61) 07 3163 4335

www.anzibdc.com   

**AUSTRALIA
NEW ZEALAND
IBD CONSORTIUM**